Skip to main content
. 2015 May 8;29(6):732–741. doi: 10.1038/eye.2015.58

Figure 2.

Figure 2

A 35-year-old man with central serous chorioretinopathy (CSC) who showed high response after single intravitreal bevacizumab treatment. Fluorescein angiography (a), indocyanine green angiography (b), and SD-OCT at baseline with thick choroid (614 μm, white arrow) (c). Complete resolution of SRF was noted at 1 month after intravitreal bevacizumab (d).